MEDIGENE | Targeting Cancer: Therapeutic TCR-T-cells | BUY coverage initiated| EUR16.1
Medigene is a developer of innovative immunotherapies based on its core T cell receptor (TCR) technology platform which has been shown to generate optimal TCRs for directing modified ‘TCR-T’ cells to kill cancer cells. The company identifies ideal cancer antigen targets and then generates the highest quality TCRs against those targets. Its other complementary platforms include one which uniquely enables it to produce monoclonal antibodies against specific TCRs (so called TABs), another which enables it to deeply monitor immune responses to therapies, and its dendritic cell (DC) vaccine platform which drives patients’ T cells to respond more effectively.Medigene is a biopharmaceutical company that focuses on the research and development of drugs to treat cancer and autoimmune diseases. Co.'s segments are: marketed products and drug candidates. Co.'s marketed products segment consists of the drug Veregen®, which is an ointment for the treatment of external genital warts. Co.'s drug candidates segment consists of: EndoTAG®-1, which is for the indication pancreatic cancer and triple-negative breast cancer; RhuDex®, which is a modifying agent for the oral treatment of autoimmune diseases; and adeno-associated virus-like particles, which provides potential as prophylactic and therapeutic vaccines, for example, against cancer and infections.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.